In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Bio-Rad Laboratories, Inc. (NYSE:BIO.B) reported that Schwartz Alice N has picked up 2,737,673 of common stock as of 2017-06-29.
The acquisition brings the aggregate amount owned by Schwartz Alice N to a total of 2,737,673 representing a 11.2% stake in the company.
For those not familiar with the company, Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.
A glance at Bio-Rad Laboratories, Inc. (NYSE:BIO.B) key stats reveals a current market capitalization of $6.79 Billion based on $5.12 Million shares outstanding and a price at last close of $226.10 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-05-26, Hinckley picked up 500 at a purchase price of $219.58. This brings their total holding to 500 as of the date of the filing.
On the sell side, the most recent transaction saw Hall unload 900 shares at a sale price of $222.65. This brings their total holding to 560.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Bio-Rad Laboratories, Inc. (NYSE:BIO.B) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.